Fluarix GlaxoSmithKline - Treatment for Influenza VaccinationFluarix is indicated for adults 18 and older against influenza disease. This approval will help toward increasing flu vaccine supply in the United States for the 2005/2006 Flu Season.
Posted: August 2005
- GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older - January 11, 2018
- FDA Approves GlaxoSmithKline's Fluarix Quadrivalent - Four-strain Seasonal Influenza Vaccine for Use in the U.S. - December 17, 2012
- FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use - October 19, 2009
- GlaxoSmithKline Submits Biologics License Application for FDA Approval of Fluarix - May 25, 2005